Evaluation of the Care Path of Patients Who Have Been Sexually Assaulted

NCT ID: NCT04078789

Last Updated: 2022-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-30

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to describe the care pathway of patients presenting in the medico-judicial unit of the Raymond Poincaré Hospital in Garches, France, following a complaint for sexual assault and suggest ways to improvement of the care adapted to the characteristics of the participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AS secondary objectives, the study aims to:

* Analyze the population of victims of sexual assault seen in consultation at the medico-judicial unit of Raymond Poincaré Hospital.
* Analyze the decision elements of the initiation of the post-exposure treatment and evaluate them against the recommendations.
* Analyze the data collected on the patients and their follow-up in consultation of infectious disease of the hospital of Garches following a sexual assault.
* Identify obstacles encountered by participants to follow the complete follow-up path.

For this purpose the data collection will be done initially within the forensic unit of Raymond Poincaré Hospital. Then, in a second step, the patients requiring the setting up of a post-exposure treatment, are addressed in the service of infectious diseases. The compilations of the data necessary for the study will then be continued until 3 months after the sexual assault.

For the collection of data, they will be based on the medical records of the victims.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sexually Transmitted Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People declared being victim of sexual assault;
* Consult at medical-legal unit;
* Judicial requirement.

Exclusion Criteria

\- Absence of judicial requirement.
Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Céline Dufort, MD

Role: PRINCIPAL_INVESTIGATOR

Unité médico-judiciaire (UMJ), Hôpital Raymond Poincaré, Garches, France

Dhiba Marigot-Outtandy, MD

Role: STUDY_DIRECTOR

Médecine aiguë spécialisée, Hôpital Raymond Poincaré, Garches, France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Céline Dufort, MD

Role: CONTACT

+33147107698

Dhiba Marigot-Outtandy, MD

Role: CONTACT

+33147107770

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP190619

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.